A combination of two drugs works better than either drug alone for patients with renal cell carcinoma, the most common form of kidney cancer, according to a pilot study led by Duke University Comprehensive Cancer Center researchers.
The effectiveness and value of an increasingly popular treatment used in the treatment of long term wounds are questioned in this month?s Drug and Therapeutics Bulletin (DTB)
Multidetector computed tomography angiography is highly accurate in depicting intracranial aneurysms, according to a study published in the August issue of Radiology. In addition, MDCT angiography can be used to quickly determine the possibility of using minimally invasive treatment rather than open surgery.
A noninvasive, outpatient treatment for noncancerous uterine tumors provides sustained relief from symptoms, according to a new Mayo Clinic led collaborative study.
For the first time, researchers using magnetic resonance imaging (MRI) have found both structural and functional abnormalities in specific brain regions of schizophrenic patients who experience chronic auditory hallucinations, according to a study published in the August issue of Radiology.
Dr. Colin McMillan, President of the Canadian Medical Association (CMA), unveiled a new vision for an expanded and modernized Medicare to serve patients.
A drug initially used to treat mild to moderate Alzheimer’s disease improved the memory and global function of people with severe Alzheimer?s disease and was safe and effective, according to a study published in the July 31, 2007, issue of Neurology?, the medical journal of the American Academy of Neurology.
GlaxoSmithKline [NYSE: GSK] welcomed the nearly unanimous recommendation of an U.S. Food and Drug Administration?s (FDA) advisory committee to support Avandia?s (rosiglitazone maleate) continued availability to patients in the US.
Melioidosis is a severe infection caused by the gram-negative bacterium, Burkholderia pseudomallei, which is endemic in Southeast Asia.
The following summarizes GlaxoSmithKline?s [NYSE: GSK] presentation of data on Avandia? (rosiglitazone maleate) to an Advisory Committee of the Food and Drug Administration (FDA) on July 30, 2007.